Story perspectives

FDA Cuts 200 Jobs, Endangers Public Health and Safety

2/21/2025

49 3

Summary

FDA Staffing Cuts

The U.S. FDA is grappling with major staffing cuts, slashing over 200 positions, including vital experts in AI and food safety. Industry leaders are sounding alarms, warning that these layoffs could stall product approvals and jeopardize patient care. Critics, including AdvaMed and former officials, label these reductions as a serious blow to public health efforts.

Summary

Bluebird Bio's Strategic Sale

Bluebird Bio has struck a deal to sell its gene therapy portfolio to Carlyle and SK Capital for less than $30 million, sidestepping bankruptcy. Shareholders could see up to $9.87 per share if the therapies thrive. This move underscores the tough reality biotech companies face in building sustainable business models amid rapid advancements in genetic medicine.

History

Historical Context

The FDA's staffing cuts echo historical challenges faced by the agency, particularly during budget constraints and political pressures. In the late 1960s, former FDA Commissioner Herbert Ley criticized the agency's inability to protect consumers due to industry influence. Similar concerns arise today as industry leaders warn that these layoffs could hinder product approvals and compromise public health, reflecting ongoing tensions between regulatory oversight and industry interests.

1 of 3

FDA Staffing Cuts

The U.S. FDA is grappling with major staffing cuts, slashing over 200 positions, including vital experts in AI and food safety. Industry leaders are sounding alarms, warning that these layoffs could stall product approvals and jeopardize patient care. Critics, including AdvaMed and former officials, label these reductions as a serious blow to public health efforts.

1 / 3